This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2021
  • /
  • 1
  • /
  • Enhertu approved in the EU for the treatment of HE...

Enhertu approved in the EU for the treatment of HER2-positive metastatic breast cancer.

Read time: 1 mins
Published:21st Jan 2021
AstraZeneca and Daiichi Sankyo Company, Limited ’s Enhertu (trastuzumab deruxtecan) has been granted conditional approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens. In Europe, approximately 531,000 cases of breast cancer in women are diagnosed annually, with an estimated one in five cases being HER2-positive. The impact of the disease is significant, with breast cancer responsible for more than 141,000 deaths per year in Europe. The approval by the European Commission was based on positive results from the single-arm DESTINY-Breast01 Phase II trial, in which Enhertu showed clinically meaningful and durable anti-tumour activity in patients with HER2-positive metastatic breast cancer who had received two or more prior anti-HER2-based regimens. It follows the December 2020 recommendation for approval by the Committee for Medicinal Products for Human Use of the European Medicines Agency, which reviewed the application under its accelerated assessment procedure.
Condition: Breast Cancer HER2+
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Related news and insights